{"transactions":[{"id":1396938,"issuer":{"id":7926,"kind":"organization","name":"Adagio Medical Holdings, Inc.","symbol":"ADGM"},"owners":[{"id":87180,"kind":"organization","name":"ARYA Sciences Holdings IV","position":1,"cik":"0001838903","reported_name":"ARYA Sciences Holdings IV","relationship":{"ten_percent_owner":true}},{"id":29191,"kind":"person","name":"Stone Adam Leo","position":2,"cik":"0001727440","reported_name":"Stone Adam Leo","relationship":{"ten_percent_owner":true}},{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":3,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-10-01T20:35:55.000Z","date":"2024-09-27","kind":"other","planned":false,"acquired":false,"shares":3501600,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 27, 2024, ARYA Sciences Holdings IV (the \"Sponsor\") effectuated a pro rata distribution for no consideration to its shareholders of its shares of common stock, par value $0.0001 per share (the \"Common Stock\"), of Adagio Medical Holdings, Inc. (f/k/a/ Aja HoldCo, Inc.) (the \"Issuer\"), including 1,147,500 shares of Common Stock that are subject to share price trigger vesting (the \"Earn-Out Shares\"). Such Earn-Out Shares (i) will vest if, prior to the tenth anniversary (the \"Earn-Out Period\") of the closing (the \"Closing\") of the business combination by and among ARYA Sciences Acquisition Corp IV, the Sponsor and the Issuer, the post-Closing share price of Common Stock equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period, or (ii) will automatically be forfeited and cancelled if the foregoing vesting condition is not fulfilled within the Earn-Out Period."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 27, 2024, ARYA Sciences Holdings IV (the \"Sponsor\") effectuated a pro rata distribution for no consideration to its shareholders of its shares of common stock, par value $0.0001 per share (the \"Common Stock\"), of Adagio Medical Holdings, Inc. (f/k/a/ Aja HoldCo, Inc.) (the \"Issuer\"), including 1,147,500 shares of Common Stock that are subject to share price trigger vesting (the \"Earn-Out Shares\"). Such Earn-Out Shares (i) will vest if, prior to the tenth anniversary (the \"Earn-Out Period\") of the closing (the \"Closing\") of the business combination by and among ARYA Sciences Acquisition Corp IV, the Sponsor and the Issuer, the post-Closing share price of Common Stock equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period, or (ii) will automatically be forfeited and cancelled if the foregoing vesting condition is not fulfilled within the Earn-Out Period."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman had voting and investment discretion with respect to any shares of Common Stock that were held of record by the Sponsor and may be deemed to have shared beneficial ownership of any shares of Common Stock that were held directly by the Sponsor."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-042486","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124042486/form4.xml","form_type":"4"}},{"id":1445045,"issuer":{"id":88618,"kind":"organization","name":"ARYA Sciences Acquisition Corp IV","symbol":"ARYD"},"owners":[{"id":87180,"kind":"organization","name":"ARYA Sciences Holdings IV","position":1,"cik":"0001838903","reported_name":"ARYA Sciences Holdings IV","relationship":{"ten_percent_owner":true}}],"security":"Class B ordinary shares","published_at":"2024-07-31T21:43:07.000Z","date":"2024-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2647500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by the Reporting Person. The Reporting Person is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Reporting Person and may be deemed to have shared beneficial ownership of the securities held directly by the Reporting Person."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":2647500},"source":{"system":"sec-edgar","filing":"0001140361-24-035169","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1838821/000114036124035169/form4.xml","form_type":"4"}},{"id":1445044,"issuer":{"id":88618,"kind":"organization","name":"ARYA Sciences Acquisition Corp IV","symbol":"ARYD"},"owners":[{"id":87180,"kind":"organization","name":"ARYA Sciences Holdings IV","position":1,"cik":"0001838903","reported_name":"ARYA Sciences Holdings IV","relationship":{"ten_percent_owner":true}}],"security":"Class B ordinary shares","published_at":"2024-07-31T21:43:07.000Z","date":"2024-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the \"Sponsor Letter Agreement\"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration."},{"field":"kind","element":"transactionCoding","label":"F3","text":"In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the \"Sponsor Letter Agreement\"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the \"Sponsor Letter Agreement\"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the \"Sponsor Letter Agreement\"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the \"Sponsor Letter Agreement\"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by the Reporting Person. The Reporting Person is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Reporting Person and may be deemed to have shared beneficial ownership of the securities held directly by the Reporting Person."}],"balance_after":2647500,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001140361-24-035169","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1838821/000114036124035169/form4.xml","form_type":"4"}},{"id":1445043,"issuer":{"id":88618,"kind":"organization","name":"ARYA Sciences Acquisition Corp IV","symbol":"ARYD"},"owners":[{"id":87180,"kind":"organization","name":"ARYA Sciences Holdings IV","position":1,"cik":"0001838903","reported_name":"ARYA Sciences Holdings IV","relationship":{"ten_percent_owner":true}}],"security":"Class A ordinary shares","published_at":"2024-07-31T21:43:07.000Z","date":"2024-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":499000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by the Reporting Person. The Reporting Person is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Reporting Person and may be deemed to have shared beneficial ownership of the securities held directly by the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-035169","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1838821/000114036124035169/form4.xml","form_type":"4"}},{"id":2818416,"issuer":{"id":88618,"kind":"organization","name":"ARYA Sciences Acquisition Corp IV","symbol":"ARYD"},"owners":[{"id":87180,"kind":"organization","name":"ARYA Sciences Holdings IV","position":1,"cik":"0001838903","reported_name":"ARYA Sciences Holdings IV","relationship":{"ten_percent_owner":true}}],"security":"Class A ordinary shares","published_at":"2021-03-02T16:30:35.000Z","date":"2021-03-02","kind":"other","acquired":true,"shares":499000,"price":10,"value":4990000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported Class A ordinary shares were purchased in a private placement from the Issuer by ARYA Sciences Holdings IV (the \"Sponsor\") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-252960)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor."}],"balance_after":499000,"source":{"system":"sec-edgar","filing":"0001140361-21-006909","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1838821/000114036121006909/form4.xml","form_type":"4"}}]}